SpringWorks Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Depreciation and amortization expense
Non-cash operating lease expense
Equity-based compensation expense
Equity method investment loss
Changes in operating assets and liabilities
Accounts receivable, net
Inventory
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued expenses
Deferred rent
Lease liability
Deferred revenue
Other liabilities

Net cash used in operating activities
Investing activities
Capital expenditures
Payment for intangible asset
Equity method investment
Purchases of marketable securities
Proceeds from sale and maturity of marketable securities
Net cash provided by (used in) investing activities
Financing activities
Proceeds from issuance of Series A convertible preferred shares, net of issuance costs
Proceeds from issuance of Series B convertible preferred shares, net of issuance costs
Proceeds from issuance of common stock
GSK
Private Placement
Market offering
Treasury stock
Proceeds from stock option exercises
Net cash provided by financing activities

Net increase (decrease) in cash and cash equivalents
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents including restricted cash, beginning of period
Cash and cash equivalents including restricted cash, end of period
Supplemental non-cash disclosure
Initial recognition of lease liabilities
Initial recognition of operating lease right of use asset
Present value of lease liabilities
Right-of-use assets obtained in exchange for operating lease obligations
Milestone payment for first commercial sale of OGSIVEO included in accrued expenses as of December 31, 2023

Comments